MedTrace Logo

Efficacy Study of Outpatient Therapy for Lymphoma

NCT00163761 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2016-01-08

No results posted yet for this study

Summary

This is a Phase II trial evaluating the efficacy (overall response rate) of a risk-adjusted outpatient based approach to lymphoma salvage therapy with vinorelbine, gemcitabine and pegfilgrastim and/or gemcitabine, ifosfamide, vinorelbine and pegfilgrastim.

Conditions

  • Non-Hodgkin's Lymphoma
  • Hodgkin's Disease

Interventions

DRUG

gemcitabine, vinorelbine, ifosfamide, filgastrim

Drug

DRUG

gemcitabine, vinorelbine, filgastrim

Drug

Sponsors & Collaborators

  • Bayside Health

    lead OTHER_GOV

Principal Investigators

  • Andrew Spencer, Assoc. Prof

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00163761 on ClinicalTrials.gov